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BACKGROUND: A synonymous single nucleotide polymorphism (SNP) rs172378 (A4G, Gly 4Gly) in the complement component
C1QA has been proposed to be associated with distant breast cancer metastasis. We previously reported overexpression of this gene
to be significantly associated with better prognosis in oestrogen-receptor-negative tumours. The purpose of this study was to
investigate the association of rs172378 with expression of C1QA and breast cancer survival.
METHODS: We analysed the gene expression pattern of rs172378 in normal and tumour tissue samples, and further explored
its involvement in relation to mortality in 2270 women with breast cancer participating in Studies of Epidemiology and Risk factors in
Cancer Heredity, a population-based case–control study.
RESULTS: We found that although rs172378 showed differential allelic expression significantly different between normal (preferentially
expressing the G allele) and tumour tissue samples (preferentially expressing the A allele), there was no significant difference
in survival by rs172378 genotype (per allele hazard ratio (HR) 1.02, 95% CI: 0.88–1.19, P¼0.78 for all-cause mortality; HR 1.03,
95% CI: 0.87–1.22, P¼0.72 for breast-cancer-specific mortality).
CONCLUSION: Our study results show that rs172378 is linked to a cis-regulatory element affecting gene expression and that allelic preferential
expression is altered in tumour samples, but do not support an association between genetic variation in C1QA and breast cancer survival.
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Complement is involved in the primary defence against intravascular
microorganisms and has been reported to be involved in the
clearance of tumour cells (Jurianz et al, 1999a,b; Golay et al,2 0 0 0 ;
Caragine et al, 2002; Fishelson et al, 2003). Recently, we have
reported an association between expression of C1QA and prognosis
in oestrogen receptor (ER)-negative breast cancer (Teschendorff
et al, 2006; Teschendorff and Caldas, 2008) in more than one cohort.
We found that ER-negative tumours with overexpression of gene
C1QA were associated with a better prognosis.
The C1QA gene, located on chromosome 1p36.12, encodes for
one of the components of the C1q complex. There are seven single
nucleotide polymorphisms (SNPs) catalogued for C1QA on
the NCBI database, of which there is only one common
SNP (minor allele frequency 45%) located in an exon rs172378
is a synonymous SNP characterised by a G for A substitution at
position 361 (A361G). This SNP has been previously reported as
being associated with breast cancer metastasis to sites linked to
hematogenous spread of disease (Racila et al, 2006) and with drug
response in follicular lymphoma (Racila et al, 2008). In a set of 63
patients with localised breast tumours and 38 patients with
metastasis, Racila et al (2006) reported a decreased time to
metastasis for G homozygote or heterozygote individuals com-
pared with the common AA homozygote (hazard ratio, 95% CI:
2.4, 1.1–4.1), even after adjustment for positive lymph nodes,
oestrogen and progesterone receptors status.
Racila et al. (2006) have also reported that rs172378 correlates
with decreased complement activity, which then reduces the
instance of metastasis associated with breast cancer, perhaps by
resulting in an inefficient clearance of apoptotic tumour cancer
cells, which consequently results in the development of a more
effective antibody response against the tumour. The same group
previously identified a correlation between the A allele of rs172378
with lower expression of the C1QA protein (Racila et al, 2003). The
purpose of this study was to investigate the association of this SNP
with expression of C1QA and breast cancer survival.
MATERIALS AND METHODS
Genotyping
Genotyping was carried out using the TaqMan platform as
per the manufacturer’s instructions. Primers and FAM- and
VIC-labelled probes were supplied directly by Applied Biosystems
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s(Foster City, CA, USA) as Assays-by-Design. All assays were carried
out as previously described (Azzato et al, 2008). Deviation from
Hardy–Weinberg equilibrium was assessed using a w
2-statistic.
Expression analysis of C1QA
Analysis of the expression of C1QA was performed in a set of blood
samples (n¼57) and normal breast tissue (n¼5, heterozygotes for
rs172378) from healthy blood donors, as well as breast tumour
tissue with normal copy number for the C1QA locus (n¼17,
heterozygotes for rs172378). Samples were obtained from the
Addenbrooke’s Hospital Tissue Bank and Blood Centre, following
ethical approval. Breast tumour cases were selected on the basis of
having normal copy number, as determined by oligonucleotide-
based array CGH analysis (Chin et al, 2007). In total, 25 samples
were excluded on the basis of having copy number aberrations
in the C1QA region, which represented approximately 25% of the
total number of samples. The demographics of the samples
analysed in this study is representative of the total group of
samples (Supplementary Table). DNA and total RNA were
extracted from these samples and cDNA was prepared with the
TaqMan Reverse Transcription Reagents kit (Applied Biosystems)
using random hexamers, according to the manufacturer’s instruc-
tions. DNA from all samples was genotyped by TaqMan analysis,
using the genotyping assay for rs172378.
Analysis of differential allelic expression was performed by
quantitative real-time allele-specific PCR, using TaqMan assay, as
previously described (Maia et al, 2009). This is the most suitable
method for testing a small to medium number of SNPs in a
relatively large number of samples, with high accuracy and
replication. In brief, the region surrounding the SNP was amplified
from cDNA of heterozygotes and the two probes, labelled
differently with FAM and VIC, have a mismatch and recognised
specifically each allele. During the real-time PCR reaction two
signals were detected in each well, one for each allele. The quantity
of each allele was extrapolated from a standard curve generated
from a dilution series of heterozygote blood DNA (50:50 allelic
ratio). Allelic expression ratios were calculated as log2((G allele
(VIC))/(A allele (FAM))). The genotyping TaqMan assay included
primers and probes within the coding region, so it was possible to
use it for the analysis of allelic expression, which was performed in
heterozygous samples only, using three replicates per assay.
Total expression levels of all samples, heterozygous and homo-
zygous for both alleles, were determined using a TaqMan Gene
Expression Assay (assay ID: Hs00381122_m1). Results were normal-
ised with the total levels of expression of actin-b,G A P D Ha n dH P R T .
Study population for association study
Cases were selected from the Studies of Epidemiology and Risk
factors in Cancer Heredity (SEARCH) breast cancer study,
an ongoing population study of women diagnosed with breast
cancer in the region of UK included in the Eastern Cancer
Registration and Information Centre (ECRIC, formerly East
Anglian Cancer Registry), as previously reported (Azzato et al,
2008). All participants in the study provided informed consent,
and the study was approved by the Eastern Multicentre Research
Ethics Committee. DNA was available from 4470 cases for
genotyping. The samples were split into two sets (set 1, n¼2270
and set 2, n¼2200) to save DNA and reduce genotyping costs.
Median age at diagnosis was similar for both sets (50 and 53 years
old, respectively). Median time from diagnosis to blood draw was
slightly longer for set 2 (18 months) than for set 1 (9 months), but
the number of deaths in each set was similar (359 in set 1 and 278
in set 2). There was no significant difference in the morphology,
histopathological grade or TNM stage of the cases by set.
Follow-up information and all-cause mortality details were
obtained based on a combination of a follow-up through the Office
of National Statistics for death notification and an active follow-up
registration and every 5-years by the ECRIC and the North Thames
Cancer Registry Breast cancer-specific mortality was defined as
deaths where breast cancer was listed as the cause of death in Part
1 of the death certificate (Azzato et al, 2008). TNM stage (1, 2, 3 or
4), which is based on tumour size (T), number of positive lymph
nodes (N) and the presence of distant metastasis (M) (Sobin and
Wittekind, 1997), and histopathological grade (well, moderately
and poorly differentiated) were obtained through ECRIC. ER status
was determined by performing immunohistochemistry on paraf-
fin-embedded sections of breast tumour using the Novocastra
clone 6F11. The Allred system was used for scoring; scores 42
were considered positive (Harvey et al, 1999).
Survival analysis statistical methods
Associations with all-cause and breast-cancer-specific mortality
were assessed for rs172378 genotype using Cox regression analysis,
modelling the time from diagnosis to death. To account for
variable time from diagnosis to recruitment, we conducted
analyses allowing for left truncated data in which cases were only
considered at risk after the date of study entry. This generates an
unbiased estimate of the HR provided the proportional hazard
assumption is correct (Azzato et al, 2009). Follow-up was censored
at the earlier of either date last known to be alive or 10 years after
diagnosis, as follow-up became less reliable after 10 years. The
proportional hazards assumption was evaluated by visual inspec-
tion of log-log plots, as well as tested analytically using Schoenfeld
residuals (Grambsch and Therneau, 1994).
A per-allele HR was estimated for rs172378 genotype
(co-dominant, log-additive model), based on the number of rare
alleles (G) carried. On the basis of previous results by Racila et al
(2006), a G dominant HR (AG/GG), relative to the common
homozygote (AA), was also estimated. Statistical significance was
assessed using a trend test (1 degree of freedom). Significant
associations with survival in set 1 at a nominal Po0.10 were
genotyped in set 2. Data from both sets can then be combined
(N¼4470) to jointly analyse associations. This joint analysis
approach results in increased power to detect genetic associations,
despite more stringent significance levels with Bonferroni
correction (Skol et al, 2006).
For multivariate models, ER status was modelled as a
dichotomous variable and age at diagnosis was modelled as a
categorical variable (o40, 40–49, 50–59 and 60þ). We compared
individual models for both TNM stage (1, 2, 3/4) and histopatho-
logical grade fitted as either continuous or categorical variables.
As the fit of each prognostic factor’s models (categorical vs
continuous) was similar, we classified these variables based on the
simplest model (continuous). ER status was found to violate the
proportional hazard assumption; as such, multivariate models
were adjusted by age, TNM stage and histopathological grade, and
stratified by ER status. A formal test of interaction between
genotype and ER status (effect beyond additive) was performed
by inclusion of an SNP-prognostic term. A test of heterogeneity
(1 degree of freedom) was used to assess for differences between
stratified parameter estimates. Statistical tests were two sided,
with an a-level of 0.05. All analyses were performed in Intercooled
Stata, version 9.2 (StataCorp LP, College Station, TX, USA).
RESULTS
Gene expression analysis of C1QA (rs172378)
The SNP rs172378 has been previously reported to have a
correlation with lower levels of C1qA in serum (Racila et al, 2003).
We analysed the correlation of total levels of C1QA and the rs172378
genotype in the blood of control individuals (Figure 1A). We did not
find a significant trend in our sample set.
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affecting the expression of C1QA, we analysed the levels of allelic
transcripts in heterozygous samples (Yan et al, 2002; Lo et al, 2003;
Udler et al, 2007; Maia et al, 2009). Using allele-specific TaqMan
PCR, we determined the allelic gene expression ratios (G allele/
A allele) in blood and breast tissue from healthy controls
heterozygous for rs172378, as well as tumour tissue from breast
cancer patients. We previously reported that the G allele was
commonly preferentially expressed in the samples from healthy
individuals, but that there were no significant differences
between blood and breast tissue (in blood, log2 mean ratio¼0.61
and s.d.¼0.52; in breast, log2 mean ratio¼0.87 and s.d.¼0.10;
P¼0.079) (Figure 1B), suggesting that there is a common cis-
regulatory element for the two types of tissue (Maia et al, 2009).
However, we now found a highly significant difference between
normal breast vs breast tumour (P¼3.8E 6) (Figure 1B). In fact,
we found that although in the normal tissues the G allele was the
preferentially expressed allele, patient tumour tissue presented
preferential expression of the alternative A allele (log2 mean
ratio¼ 0.39 and s.d.¼0.61). We found no significant differences
between the differential allelic expression ratio of tumours
stratified on ER status (Figure 1B).
Survival analysis
The characteristics of the SEARCH breast cancer cases that have
been included in this report are summarised in Table 1. Cases were
followed for a median of 7.75 years (from 6.72 months to 10 years).
During the 13851.3 person-years at risk there were 359 deaths
before the 10 years follow-up, of which 305 were coded as due to
breast cancer.
Genotyping for C1QA rs172378 was successful for 2168
individuals (95.2%); genotype frequencies are presented in Table 2.
This SNP did not deviate from Hardy–Weinberg equilibrium in
this population (P¼0.62).
The results from the survival analyses for the co-dominant and
AG/GG vs GG models for both all-cause and breast-cancer-specific
mortality are presented in Table 3. C1QA rs172378 genotype did
not show evidence of proportional hazard assumption violation in
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Figure 1 Gene expression analysis of CIQA.( A) Analysis of total level of gene expression by genotype at the rs172378 polymorphism, in blood samples
from healthy control individuals. (B) Analysis of differential allelic expression in heterozygous samples for the rs172378 polymorphism in control blood,
control breast tissue and tumour breast tissue; data points for tumour samples are shown as a closed triangle for oestrogen receptor (ER)-positive samples
and as an open triangle for ER-negative samples. In both plots, the number of data points is indicated below each boxplot. Significant t-tests are indicated
by asterisk (*).
Table 1 SEARCH participant characteristics
Total number of subjects 2270
Total time at risk (years) 13851.3
Median follow-up (years)
a 7.75 (0.56–10)
b
Median time at risk (years) 6.47 (0.10–9.64)
b
Median time from diagnosis to study
entry (years)
0.73 (0.00–8.64)
b
Number of deaths 359
Annual mortality rate 0.026 (0.023–0.029)
c
5-year survival rate 0.88 (0.86–0.89)
c
Median age at diagnosis (years) 50.2 (25–69)
b
Age at diagnosis
o40 212 9.3%
40–49 753 33.2%
50–59 997 43.9%
60+ 308 13.6%
Histopathological grade
Well differentiated 437 19.3%
Moderately differentiated 788 34.7%
Poorly differentiated 505 22.3%
Unknown 540 23.8%
Morphological type
Ductal 1674 73.7%
Lobular 351 15.5%
Other 222 9.8%
Unknown 23 1.0%
Clinical stage
1 1114 49.1%
2 987 43.5%
3 or 4 110 4.9%
Missing 59 2.6%
ER Status
ER negative 363 16.0%
ER positive 856 37.7%
Missing 1051 46.3%
Abbreviation: ER¼oestrogen receptor.
aFollow-up censored at 10 years.
bRange of
variable.
c95% CI.
C1QA genetic variation and breast cancer survival
EM Azzato et al
1296
British Journal of Cancer (2010) 102(8), 1294–1299 & 2010 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
seither model (all P’s40.10). We found no evidence that overall
survival varied by rs172378 genotype, either in the co-dominant
model (per-rare-allele HR¼1.01, 95% CI: 0.81–1.25, P¼0.95) or
the rare dominant model (HRAG/GG vs AA¼0.83, 95% CI: 0.61–1.13,
P¼0.24), adjusted for age at diagnosis, TNM stage, histopatho-
logical grade and ER status. Results were consistent for breast-
cancer-specific mortality. As we recently reported an association
between C1QA expression and survival in ER-negative breast
cancer, we also performed adjusted analyses stratified by ER
status. No statistically significant associations were observed
and there was no evidence of the HR varying by ER status
(all heterogeneity P40.10). In addition, formal tests of interaction
by ER status were non-significant in all the models (all P’s40.10).
As no association reached nominal level of significance in set 1 (all
P’s40.10), we did not genotype this SNP in set 2.
DISCUSSION
The complement system and its inhibitors have been shown to be
important in clearing tumour cells (Jurianz et al, 1999a,b; Golay
et al, 2000; Caragine et al, 2002; Fishelson et al, 2003). Recently, we
showed that overexpression of C1QA in ER-negative basal-like
breast cancer patients, which have the poorest prognosis (Sorlie
et al, 2001), is associated with better outcome (Teschendorff et al,
2006, 2007; Teschendorff and Caldas, 2008).
The A allele of C1QA polymorphism rs172378 has been
associated with decreased complement activity, resulting in
reduced metastasis associated with breast cancer (Petry and Loos,
2005; Racila et al, 2006). The decrease in complement activity is
suggested to result in less clearance of apoptotic tumour cells
(Racila et al, 2003), and in a more effective antibody response
against the tumour. Also, this same allele has been reported to
associate with lower levels of serum C1qA protein (Racila et al,
2003). Therefore, we hypothesised that the A allele, or another
allele in tight linkage disequilibrium, could have a regulatory role
and could correlate with lower expression of C1qA.
We investigated the association of the rs172378 with gene
expression in normal and patient samples. We found no
correlation between the genotype at rs172378 and the level of
expression of C1QA in fresh blood samples (P¼0.07), but there
was a trend towards higher mean total expression of C1qA in
individuals with the G allele. Previously, when we examined the
same samples for differential allelic expression we found that in
both fresh blood and normal breast tissue there was consistent
preferential expression of the G allele (log2 mean fold ratio
G/A¼0.87), which indicates that rs172378 is linked to a functional
cis-regulatory element (Maia et al, 2009). This cis-element may be
situated within or very close to the gene, as the linkage
disequilibrium block where rs172378 lies is 11.9kb long and
includes the whole gene (3.1kb) as well as up- and downstream
regions. This finding suggests that the reported correlation
between the A allele and lower levels of C1qA in serum could be
associated not with translational regulation, but instead with
transcriptional regulation.
Now we found that in tumour samples differential expression
was also present, but the majority preferentially expressed the
A allele (log2 mean fold ratio G/A¼ 0.39 for tumours), which is
Table 2 C1qA rs172378 genotype frequency in SEARCH study
Genotype N Frequency (%)
AA 822 36.2
AG 1031 45.4
GG 309 13.6
Missing 108 4.8
Total 2270
MAF 0.44
Abbreviation: MAF¼minor allele frequency.
Table 3 Survival analysis
Model HR (95% CI) P
ER status
interaction P
a
ER status
heterogeneity P
b
All-cause mortality
Co-dominant
All tumours (unadjusted) 1.02 (0.88–1.19) 0.78
All tumours (adjusted)
c 1.01 (0.81–1.25) 0.95
ER+ tumours only
d 1.17 (0.82–1.66) 0.39
ER  tumours only
d 0.94 (0.71–1.24) 0.66 0.74 0.34
AG/GG vs AA
All tumours (unadjusted) 0.92 (0.74–1.15) 0.74
All tumours (adjusted)
c 0.83 (0.61–1.13) 0.24
ER+ tumours only
d 0.80 (0.50–1.28) 0.36
ER  tumours only
d 0.87 (0.57–1.32) 0.52 0.54 0.80
Breast-cancer-specific mortality
Co-dominant
All tumours (unadjusted) 1.03 (0.87–1.22) 0.72
All tumours (adjusted)
c 1.02 (0.81–1.28) 0.89
ER+ tumours only
d 1.07 (0.72–1.59) 0.75
ER  tumours only
d 1.02 (0.77–1.37) 0.87 0.72 0.87
AG/GG vs AA
All tumours, unadjusted 0.92 (0.73–1.16) 0.47
All tumours (adjusted)
c 0.84 (0.60–1.18) 0.33
ER+ tumours only
d 0.75 (0.44–1.25) 0.27
ER  tumours only
d 0.96 (0.61–1.50) 0.84 0.31 0.48
Abbreviation: CI¼confidence interval; ER¼oestrogen receptor; HR¼hazards ratio. HRs, 95% CIs and P-values under co-dominant and dominant C1qA rs172378 genotype
models for all-cause and breast-cancer-specific mortality.
aFormal test for interaction (effect beyond additive) between C1qA genotype and ER status.
bOne degree of freedom
w
2-test for heterogeneity between ER+/  tumor HRs.
cModels adjusted for age at diagnosis (o40, 40–49, 50–59, 60+), TNM stage, histopathological grade and stratified by ER
status.
dModels adjusted for age at diagnosis (o40, 40–49, 50–59, 60+), TNM stage, histopathological grade.
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sassociated with less C1QA expression. The change in the
preferentially expressed allele from control to tumour tissue
remains unexplained. The change observed in tumour samples
could be caused by the interaction of the same cis-element with
different transcription factors when in the tumour environment, or
could be a consequence of a different functional polymorphism
specific to the tumour samples. This could also suggest that a less
efficient complement activity could be associated with tumour
development, due to a less efficient clearance of tumour cells.
However, C1QA expressed by other tissues, for example liver,
could produce a compensation effect.
Information on the ER status of the analysed tumours was
available, and although the difference is not statistically significant
(t-test P¼0.26) there seems to exist a trend for ER-positive
patients to have a higher differential allelic expression ratio,
meaning a higher contribution of the G allele to the total
expression of C1QA. We did not have sufficient ER-negative
tumours to perform a correlation analysis of C1QA differential
expression and clinical data, but all data, ours and of others, seem
to suggest the lower expression of C1QA, which is associated with
preferential expression of the A allele, could be linked to the worst
prognosis associated with ER-negative tumours.
Next we evaluated the impact of rs172378 on breast cancer
survival among women from the East Anglian region of the UK.
This is a large-sized population-based study, characterised by a
long and systematic follow-up. We have found no evidence that
rs172378 is associated with outcome after a diagnosis of breast
cancer, including stratification by ER status. Under our staged
design, assuming a co-dominant model, a minor allele frequency of
0.44 and a joint analysis a level of 0.05, we had 97% power to detect
an HR of 1.3. Power was not as good for the dominant (AG/GG vs
AA) model, where we had 72% power to detect the same effect;
however, power is 100% for HRs above 1.5, leaving our study more
than adequately powered to detect a dominant effect similar to the
one reported by Racila et al (2008). On the basis of our earlier
finding that C1QA expression was associated with survival in
ER-negative tumours, we stratified our sample by ER status.
As ER-negative tumours are the minority of our cases (N¼363),
power to detect differential survival in this subgroup is somewhat
less: assuming a co-dominant model, we have 86% power to detect
an HR of 1.5 and 100% power to detect an HR of 1.7 or higher.
Further, due to limited treatment information about these patients,
we did not evaluate the effect of rs172378 on survival in treatment
subgroups.
Overall, our data do not support the association of rs172378 with
survival previously reported, but we have identified the existence
of a cis-regulatory genetic variation that affects the expression of
C1QA, and could explain the previously reported association of the
A allele with lower C1qA protein in serum.
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